Angulo, David

The emerging pathogen Candida auris: growth phenotype, virulence factors, activity of antifungals, and effect of SCY-078, a novel glucan synthesis inhibitor, on growth morphology and biofilm formation

Larkin, E., Hager, C., Chandra, J., Mukherjee, P. K., Retuerto, M., Salem, I., Long, L., Isham, N., Kovanda, L., Borroto-Esoda, K., et al. (2017) · Antimicrobial Agents and Chemotherapy

Antifungal resistance and susceptibilityFungal and yeast genetics research

Cited by 395

De Novo Acquisition of Resistance to SCY-078 in Candida glabrata Involves FKS Mutations That both Overlap and Are Distinct from Those Conferring Echinocandin Resistance

Jiménez-Ortigosa, C., Perez, W. B., Angulo, D., Borroto-Esoda, K., & Perlin, D. S. (2017) · Antimicrobial Agents and Chemotherapy

Antifungal resistance and susceptibilityFungal Plant Pathogen Control

Cited by 89

MSG-10: a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis

Spec, A., Pullman, J., Thompson, G. R., Powderly, W. G., Tobin, E. H., Vazquez, J., Wring, S. A., Angulo, D., Helou, S., Pappas, P. G., et al. (2019) · Journal of Antimicrobial Chemotherapy

Antifungal resistance and susceptibilityFungal Infections and Studies

Cited by 88

SCY-078 is fungicidal against Candida species in time-kill studies

Scorneaux, B., Angulo, D., Borroto-Esoda, K., Ghannoum, M., Peel, M., & Wring, S. (2017) · Antimicrobial Agents and Chemotherapy

Antifungal resistance and susceptibilityFungal Plant Pathogen Control

Cited by 88

Ibrexafungerp Versus Placebo for Vulvovaginal Candidiasis Treatment: A Phase 3, Randomized, Controlled Superiority Trial (VANISH 303)

Schwebke, J. R., Sobel, R., Gersten, J. K., Sussman, S. A., Lederman, S. N., Jacobs, M. A., Chappell, B. T., Weinstein, D. L., Moffett, A. H., Azie, N. E., et al. (2022) · Clinical Infectious Diseases

Antifungal resistance and susceptibilityReproductive tract infections research

Cited by 82

In Vitro Activity of Ibrexafungerp, a Novel Glucan Synthase Inhibitor against Candida glabrata Isolates with FKS Mutations

Nunnally, N. S., Etienne, K. A., Angulo, D., Lockhart, S. R., & Berkow, E. L. (2019) · Antimicrobial Agents and Chemotherapy

Antifungal resistance and susceptibilityFungal Plant Pathogen Control

Cited by 66

Ibrexafungerp, a Novel Oral Triterpenoid Antifungal in Development: Overview of Antifungal Activity Against Candida glabrata

Gamal, A., Chu, S., McCormick, T. S., Borroto-Esoda, K., Angulo, D., & Ghannoum, M. A. (2021) · Frontiers in Cellular and Infection Microbiology

Antifungal resistance and susceptibilityFungal Plant Pathogen Control

Cited by 58

Oral Ibrexafungerp: An Investigational Agent for the Treatment of Vulvovaginal Candidiasis

Azie, N., Angulo, D., Dehn, B., & Sobel, J. D. (2020) · Expert Opinion on Investigational Drugs

Antifungal resistance and susceptibilityReproductive tract infections research

Cited by 46

SCY-078 Demonstrates Significant Tissue Penetration in Rats and Mice Following Oral or IV Administration

Barat, S., Borroto-Esoda, K., & Angulo, D. (2017) · Open Forum Infectious Diseases

Antifungal resistance and susceptibilityAntibiotics Pharmacokinetics and Efficacy

Cited by 1